NDA 020201 · Hospira
Dobutamine Hydrochloride In Dextrose 5% In Plastic Container
Dobutamine Hydrochloride · Intravenous
Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Sep 27, 1993
Approved uses
1
Original approval plus efficacy supplements
Registered trials
80
14 Phase 3, 7 recruiting
FAERS reports
4
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 6, 2026.
INDICATIONS AND USAGE Dobutamine in 5% Dextrose Injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 27, 1993 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
- DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 400MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
- DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 100MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
- DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 50MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
- DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 200MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Dobutamine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
AbbottIndustry
NCT00348504 · 1,300 participants · Start Mar 2003
Drug: levosimendan; dobutamine · For: Acute Heart Failure
Sites: Abbott Park, Illinois
- Dobutamine for Management of Surgical Patients With Septic ShockPivotal-lookingCompleted
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT06462313 · 584 participants · Start Jun 18, 2024 · Primary completion Nov 15, 2025
Drug: Dobutamine; Norepinephrine · For: Patients With Septic Shock; Surgical Patients; General Anesthesia
Sites: Hangzhou, China
- Unloading in Heart Failure Cardiogenic ShockPivotal-lookingNot yet recruiting
Amsterdam UMC, location VUmcAcademic, hospital or other
NCT05064202 · 456 participants (planned) · Start Oct 1, 2023 · Primary completion Oct 1, 2027
Drug: Inotropes · For: Cardiogenic Shock
Sites: Amsterdam, Netherlands; Groningen, Netherlands; Leiden, Netherlands · 5 sites in all
Lantheus Medical ImagingIndustry
NCT00162370 · 400 participants · Start Apr 2004 · Primary completion Sep 2012
Drug: Perflutren Lipid Microsphere Injectable Suspension · For: Coronary Artery Disease; Heart Disease
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
- CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic ShockPivotal-lookingRecruiting
Ottawa Heart Institute Research CorporationAcademic, hospital or other
NCT05267886 · 346 participants (planned) · Start Mar 5, 2022 · Primary completion Dec 2026
Drug: Dobutamine; Milrinone and 1 more · For: Shock, Cardiogenic
Sites: Rochester, Minnesota; Hamilton, Canada; Ottawa, Canada
- Norepinephrine Plus Dobutamine Versus Epinephrine Alone for the Management of Septic ShockPivotal-lookingCompleted
University of VersaillesAcademic, hospital or other
NCT00148278 · 330 participants · Start Oct 1999 · Primary completion Dec 2004
Drug: norepinephrine and dobutamine; epinephrine plus placebo of dobutamine · For: Septic Shock; Severe Sepsis; Infections
Sites: Colombes, France; Corbeil, France; Garches, France · 15 sites in all
- Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for RevascularizationPivotal-lookingCompleted
Medstar Health Research InstituteAcademic, hospital or other
NCT00074724 · 319 participants · Start May 2003 · Primary completion Dec 2008
Drug: Modern medical management; Optimal medical therapy · For: Cardiovascular Diseases; Coronary Disease; Heart Failure and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthenia1
- blood pressure increased1
- burkholderia test positive1
- device issue1
- dizziness1
- drug monitoring procedure not performed1
- drug therapeutic incompatibility1
- heart rate increased1
- product deposit1
- product packaging confusion1
- wrong product stored1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2022 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 9, 2026
Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (1 mg/mL) (NDC 0409-0025-10).
Current · updated Nov 9, 2026
Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (4 mg/mL) (NDC 0409-1100-10).
Current · updated Nov 9, 2026
Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (2 mg/mL) (NDC 0409-0151-10).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.
Jia L, Wang P, Li C, et al. · Shock 2023 · Systematic Review, Network Meta-Analysis
- Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
Mathew R, Di Santo P, Jung RG, et al. · N Engl J Med 2021 · Comparative Study, Pragmatic Clinical Trial
- CMR imaging for the evaluation of myocardial stunning after acute myocardial infarction: a meta-analysis of prospective trials.
Romero J, Kahan J, Kelesidis I, et al. · Eur Heart J Cardiovasc Imaging 2013 · Meta-Analysis, Systematic Review
- Levosimendan in paediatric cardiac anaesthesiology: A systematic review and meta-analysis.
Lapere M, Rega F, Rex S · Eur J Anaesthesiol 2022 · Meta-Analysis, Systematic Review
- Efficacy of Levosimendan in the Treatment of Patients With Severe Septic Cardiomyopathy.
Sun T, Zhang N, Cui N, et al. · J Cardiothorac Vasc Anesth 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Mebazaa A, Nieminen MS, Packer M, et al. · JAMA 2007 · Comparative Study, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.